Maternal autoimmune diseases and immunologically induced embryonic and fetoplacental damage

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 70, Issue 6, 2004, Pages 371-381

  Ornoy, Asher ^a   Chen, Limor ^a   Silver, Robert M ^b   Miller, Richard K ^c  

^a HEBREW UNIVERSITY   (Israel)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; AUTOANTIBODY; ENOXAPARIN; FOLIC ACID; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; AUTOIMMUNE DISEASE; CELL GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; EMBRYO; EMBRYO DEATH; EMBRYOPATHY; EXPLANT; FEMALE; FETOPLACENTAL UNIT; FETUS WASTAGE; HUMAN; HUMAN TISSUE; MATERNAL DISEASE; NONHUMAN; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RAT; RECURRENT DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TROPHOBLAST;

ABORTION, HABITUAL; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; EMBRYO; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; ORGAN CULTURE TECHNIQUES; PLACENTA; PLATELET AGGREGATION INHIBITORS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RATS;

ANIMALIA;

EID: 3042725367     PISSN: 15420752     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdra.20021     Document Type: Conference Paper

References (76)

1. Aggarwal N, Sawhney H, Vasishta K, et al. 1999. Pregnancy in patients with systemic lupus erythematosus. Aust N Z J Obstet Gynaecol 39:28-30.
2. Alarcon-Segovia D, Sanchez-Guerrero J. 1989. Primary antiphospholipid syndrome. J Rheumatol 16:482-488.
3. Andree HA, Stuart MC, Hermens WT, et al. 1992. Clustering of lipid-bound annexin V may explain its anticoagulant effect. J Biol Chem 267:17907-17912.
4. Asherson RA, Khamashta MA, Ordi-Ros J, et al. 1989. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 68:366-374.
5. Asherson RA, Cervera R, Piette JC, et al. 1998. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77:195-207.
6. Blank M, Cohen J, Toder V, et al. 1991. Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 88: 3069-3073.
7. Blank M, Tincani A, Shoenfeld Y. 1994. Induction of experimental antiphospholipid syndrome in naive mice with purified IgG antiphosphatidylserine antibodies. J Rheumatol 21:100-104.
8. Boutjdir M. 2000. Molecular and ionic basis of congenital complete heart block. Trends Cardiovasc Med 10:114-122.
9. Branch DW. 1990. Autoimmunity and pregnancy loss. JAMA 244:1453-1454.
10. Branch DW, Silver RM, Blackwell JL, et al. 1992. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 80:614-620.
11. Branch DW, Khamashta MA. 2003. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 101:1333-1344.
12. Buyon JP, Hiebert R, Copel J, et al. 1998. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 31:1658-1666.
13. Buyon JP. 1999. Neonatal lupus syndromes. In: Lahita R, editor. Systemic lupus erythematosus. 3rd ed. San Diego, CA: Academic Press. pp. 337-359.
14. Buyon JP, Clancy RM. 2003. Neonatal lupus syndromes. Curr Opin Rheumatol 15:535-541.
15. Cariou R, Tobelem G, Bellucci S, et al. 1988. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells-inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 60:54-58.
16. Cervera R, Font J, Lopez-Soto A, et al. 1990. Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis 49:109-113.
17. Cervera R, Piette JC, Font J, et al. 2002. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46:1019-1027.
18. Cervera R, Vinas O, Ramos-Casals M, et al. 2003. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 62:431-434.
19. Cho CS, Cho ML, Chen PP, et al. 2002. Antiphospholipid antibodies induce monocyte chemo-attractant protein-1 in endothelial cells. J Immunol 168:4209-4215.
20. Cimaz R, Spence DL, Hornberger L, et al. 2003. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 142:678-683.
21. da Costa M, Sequeira JM, Rothenberg S, et al. 2003. Antibodies to folate receptors impair embryogenesis and fetal development in the rat. Birth Defects Res Part A Clin Mol Teratol 67:837-47.
22. De Wolf F, Carreras LO, Moerman P, et al. 1982. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 142:829-834.
23. Entrican G. 2002. Immune regulation during pregnancy and host-pathogen interactions in infectious abortion. J Comp Pathol 126:79-94.
24. Genbacev O, Schubach SA, Miller RK. 1992. Villous culture of first trimester human placenta-model to study extravillous trophoblast (EVT) differentiation. Placenta 13:439-461.
25. Ginsberg JS, Greer I, Hirsh J. 2001. Use of antithrombotic agents during pregnancy. Chest 119:122S-131S.
26. Gustafsson E, Arvola M, Brunsberg U, et al. 1997. Lack of detectable major histocompatibility complex class II a beta-chain messenger ribonucleic acid in placentas of interferon-gamma- and 5-azacytidine-treated mice. Biol Reprod 57:715-722.
27. Hanly JG. 2003. Antiphospholipid syndrome: an overview. CMAJ 168: 1675-1682.
28. Harris EN. Special report. 1990. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 94:476-484.
29. Hayslett JP. 1992. The effect of systemic lupus erythematosus on pregnancy and pregnancy outcome. Am J Reprod Immunol 28:199-204.
30. Holers VM, Girardi G, Mo L, et al. 2002. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 195:211-220.
31. Horkko S, Miller E, Dudl E, et al. 1996. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 98:815-825.
32. Hughes G. 2003. Materno-fetal transmission of autoimmune disease. Vaccine 21:3426-3427.
33. Huynh TV, Chen F, Wetzel GT, et al. 1992. Developmental changes in membrane Ca2+ and K+ currents in fetal, neonatal, and adult rabbit ventricular myocytes. Circ Res 70:508-515.
34. Ito T, Ikeda U. 2003. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets Inflamm Allergy 2:257-265.
35. Khong TY, De Wolf F, Robertson WB, et al. 1986. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 93:1049-1059.
36. Lee LA. 1993. Neonatal lupus erythematosus. J Invest Dermatol 100:9S-13S.
37. Levine JS, Branch DW, Rauch J. 2002. The antiphospholipid syndrome. N Engl J Med 346:752-763.
38. Lockshin MD, Druzin ML, Goei S, et al. 1985. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus. N Engl J Med 313:152-156.
39. Lockshin MD. 1997. Antiphospholipid antibody. Babies, blood clots, biology. JAMA 277:1549-1551.
40. Loke YW, King A. 1997. Immunology of human placental implantation: clinical implications of our current understanding. Mol Med Today 3:153-159.
41. Mackworth-Young CG, Loizou S, Walport MJ. 1989. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 48:362-367.
42. Matalon ST, Shoenfeld Y, Blank M, et al. 2002. The effects of IgG purified from women with SLE and associated pregnancy loss on rat embryos in culture. Am J Reprod Immunol 48:296-304.
43. Matalon ST, Shoenfeld Y, Blank M, et al. 2004. Anti-phosphatidylserine antibodies affect yolk sacs in culture: A mechanism for fetal loss in antiphospholipid syndrome. Am J Reprod Immunol 51:144-151.
44. Mok CC, Lau CS. 2003. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56:481-490.
45. Mosser G, Ravanat C, Freyssinet JM, et al. 1991. Sub-domain structure of lipid-bound annexin-V resolved by electron image analysis. J Mol Biol 217:241-245.
46. Nayar R, Lage JM. 1996. Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Hum Pathol 27:201-216.
47. Ornoy A, Yacobi S, Avraham S, et al. 1998. The effect of sera from women with systemic lupus erythematosus and/or antiphospholipid syndrome on rat embryos in culture. Reprod Toxicol 12:185-191.
48. 12 and 20% fetal bovine serum. J Anatomy 203: 419-423.
49. Omoy A, Yacobi S, Matalon ST, et al. 2003b. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 12:573-578.
50. Oshiro BT, Silver RM, Scott JR, et al. 1996. Antiphospholipid antibodies and fetal death. Obstet Gynecol 87:489-493.
51. Out HJ, Kooijman CD, Bruinse HW, et al. 1991. Histopathological findings in placentae from patients with intra-uterine fetal death and antiphospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 41:179-186.
52. Pierangeli SS, Liu SW, Anderson G, et al. 1996. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation 94:1746-1751.
53. Pierangeli SS, Colden-Stanfield M, Liu X, et al. 1999. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation 99:1997-2002.
54. Pittoni V, Isenberg D. 1998. Apoptosis and antiphospholipid antibodies. Semin Arthritis Rheum 28:163-178.
55. Rand JH. 2002. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 90:29-37.
56. Rand JH, Wu XX, Quinn AS, et al. 2003. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 163:1193-1200.
57. Reviakine II, Bergsma-Schutter W, Brisson A. 1998. Growth of protein 2-D crystals on supported planar lipid bilayers imaged in situ by AFM. J Struct Biol 121:356-361.
58. Rothenberg SP, da Costa MP, Sequeira JM, et al. 2004. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 350:134-142.
59. Salafia CM, Parke AL. 1997. Placental pathology in systemic lupus erythematosus and phospholipid antibody syndrome. Rheum Dis Clin North Am 23:85-97.
60. Salmon JE, Girardi G, Holers VM. 2002. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 61ii:46-50.
61. Salomonsson S, Dorner T, Theander E, et al. 2002. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 46:1233-1241.
62. Shoenfeld Y, Sherer Y, Blank M, et al. 1998. Antiphospholipid antibodies in pregnancy. Scand J Rheumatol 107:33-36.
63. Silver RK, Adler L, Hickman AR, et al. 1991. Anticardiolipin antibody-positive serum enhances endothelial cell platelet-activating factor production. Am J Obstet Gynecol 165:1748-1752.
64. Silver RM, Porter TF, van Leeuween I, et al. 1996. Anticardiolipin antibodies: clinical consequences of "low titers". Obstet Gynecol 87:494-500.
65. Silver RM, Smith LA, Edwin SS, et al. 1997. Variable effects on murine pregnancy of immunoglobulin G fractions from women with antiphospholipid antibodies. Am J Obstet Gynecol 177:229-233.
66. Simantov R, LaSala JM, Lo SK, et al. 1995. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96:2211-2219.
67. Tannenbaum SH, Finko R, Cines DB. 1986. Antibody and immune complexes induce tissue factor production by human endothelial cells. J Immunol 137:1532-1537.
68. Thellin O, Heinen E. 2003. Pregnancy and the immune system: between tolerance and rejection. Toxicology 185:179-184.
69. Tran HB, Macardle PJ, Hiscock J, et al. 2002b. Anti-La/SSB antibodies transported across the placenta bind apoptotic cells in fetal organs targeted in neonatal lupus. Arthritis Rheum 46:1572-1579.
70. Tran HB, Ohlsson M, Beroukas D, et al. 2002a. Subcellular redistribution of Ia/SSB autoantigen during physiologic apoptosis in the fetal mouse heart and conduction system: a clue to the pathogenesis of congenital heart block. Arthritis Rheum 46:202-208.
71. Van Venrooij WJ, Sillekens PT. 1989. Small nuclear RNA associated proteins: autoantigens in connective tissue diseases. Clin Exp Rheumatol 7:635-645.
72. Voges D, Berendes R, Burger A, et al. 1994. Three-dimensional structure of membrane-bound annexin V. A correlative electron microscopy-X-ray crystallography study. J Mol Biol 238:199-213.
73. Wilson WA, Gharavi AE, Koike T, et al. 1999. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42:1309-1311.
74. Wright GJ, Jones M, Puklavec MJ, et al. 2001. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology 102:173-179.
75. Xu C, Mao D, Holers VM, et al. 2000. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 287:498-501.
76. Yacobi S, Ornoy A, Blumenfeld Z, et al. 2002. Effect of sera from women with systemic lupus erythematosus or antiphospholipid syndrome and recurrent abortions on human placental explants in culture. Teratology 66:300-308.